Back to BAKER BROS. ADVISORS LP BAKER BROS. ADVISORS LP

CLDXCLDX
Showing 8 of 11 quarters

Position history for BAKER BROS. ADVISORS LPBAKER BROS. ADVISORS LP's holdings in Celldex Therapeutics, Inc.

BAKER BROS. ADVISORS LP holds 1.2M shares of CLDX (Celldex Therapeutics, Inc.), worth $44M as of 2026-Q2. The position was increased (+77.7% shares). CLDX represents 0.2% of BAKER BROS. ADVISORS LP's portfolio.

Current Value

$44M

Current Shares

1.2M

Total Value Change

+$35.6M

Total Shares Change

+934,967

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.2M
+77.7%
$44M0.2%$37.21
53
2026-Q1
Unchanged
665,370
0.0%
$21.1M0.1%$28.94
0
2025-Q4
Unchanged
665,370
0.0%
$18.1M0.1%$26.43
0
2025-Q3
Unchanged
665,370
0.0%
$17.2M0.1%$26.19
0
2025-Q2
Increased
665,370
+168.7%
$13.5M0.1%$20.29
54
2025-Q1
Unchanged
247,644
0.0%
$4.5M0.0%$19.93
0
2024-Q4
Unchanged
247,644
0.0%
$6.3M0.1%$25.12
0
2024-Q3
Unchanged
247,644
0.0%
$8.4M0.1%$33.20
0

Other major holders of CLDX: BNP PARIBAS FINANCIAL MARKETS, WELLINGTON MANAGEMENT GROUP LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used